Skip to main content
Grafa
Health
Integral Diagnostics expects $790M in FY26 revenue
Image for illustrative purposes only. Not a real photo.

Integral Diagnostics expects $790M in FY26 revenue

Share
  • Integral Diagnostics announced preliminary FY26 revenue expectations between $788 million and $790 million.
  • The initial market reaction left the company's shares trading flat at $2.16.
  • Integral Diagnostics stated that operational discipline supported its continued debt reduction trajectory.

Integral Diagnostics (ASX:IDX) expects preliminary FY26 revenue to reach between $788 million and $790 million.

The expected result compares against the $628 million recorded during the previous financial year.

Operating EBITDA for the period is expected to reach $164 million to $165 million.  The company stated operating net profit after tax is projected to reach $47–48 million.

Integral Diagnostics indicated that group replacement and growth capital expenditure totalled approximately $50 million.

The company also appointed Jenny Martin as the company’s new CFO, effective Oct. 5.

Following the announcement, the Integral Diagnostics share price was unchanged at $2.16.

The business stated that its operating debt ratio improved to an estimated 2.3 times.

Frequently asked questions